Status:

WITHDRAWN

Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children

Lead Sponsor:

The Hospital for Sick Children

Collaborating Sponsors:

C17 Council (regulatory sponsor)

Conditions:

Hospitalized Children

Covid-19 Infection

Eligibility:

All Genders

Up to 18 years

Phase:

PHASE2

Brief Summary

This is a multicentered, open-label, randomized controlled Phase 2 trial to evaluate the safety and efficacy of providing human coronavirus-immune convalescent plasma as treatment for COVID-19 disease...

Detailed Description

SARS-CoV-2 viral infection resulting in COVID-19 disease has recently been designated by the World Health Organization as a global pandemic. Outbreak forecasting and mathematical models suggest that t...

Eligibility Criteria

Inclusion

  • Age 0 to \<19 years old
  • Hospitalized with symptoms compatible with COVID-19 illness
  • Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen prior to randomization.
  • ABO compatible convalescent plasma available

Exclusion

  • Onset of symptoms began \>12 days before screening
  • History of adverse reactions to blood products or other contraindication to transfusion
  • Refusal of plasma for religious or other reasons
  • Acute heart failure with fluid overload
  • Any condition or diagnosis, that could in the opinion of the Site Principal Investigator interfere with the participant's ability to comply with study instructions, or put the participant at risk
  • Anticipated discharge within 24 hours
  • Note: The intent of this exclusion criteria is to only include participants with acute COVID-19 infections. This protocol is not intended to include participants with post-infectious complications. In cases where the distinction is not clear, participant eligibility will be discussed with the study steering committee prior to enrollment.

Key Trial Info

Start Date :

October 7 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2022

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04377568

Start Date

October 7 2020

End Date

May 1 2022

Last Update

April 23 2021

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Alberta Children's Hospital

Calgary, Alberta, Canada, T3B 6A8

2

Stollery Children's Hospital

Edmonton, Alberta, Canada, T6G 2B7

3

BC Children's Hospital

Vancouver, British Columbia, Canada, V6H 3V4

4

Winnipeg Children's Hospital

Winnipeg, Manitoba, Canada, R3C 1X7